ArticleFrontiers in endocrinology2026
Effect of RAS inhibitors on retinal microvasculature in DKD using AI-based ultra-wide-field images.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) and diabetic retinopathy (DR) represent two major microvascular complications of diabetes mellitus (DM). Previous studies have suggested that renin-angiotensin system inhibitors (RASi) exert protective effects on both DKD and DR. However, their specific impact on retinal microvascular parameters (RMPs), as well as the association between changes in fundus microvasculature and alterations in renal clinical parameters, remains unclear. This pilot study aimed to quantitatively assess the short-term effects of RASi on retinal microvasculature in patients with DKD using an artificial intelligence (AI)-based analysis of ultra-wide-field (UWF) fundus images. Methods: In this prospective cohort study, 27 patients with DKD were enrolled between July 2023 and September 2024. UWF fundus images were acquired at baseline and 12 weeks after initiation of RASi therapy. A validated deep learning AI model was employed to segment retinal vessels and quantify RMPs, including fractal dimension (D Results: Among the enrolled patients, 21 patients (77.8%) were male, with a mean age of 55.7 ± 14.2 years, a mean diabetes duration of 9.9 ± 6.6 years, a baseline estimated glomerular filtration rate (eGFR) of 73.7 ± 18.5 mL/min/1.73 m², and a median proteinuria of 0.57 (0.25, 0.97) g/24h. Fifteen patients (55.6%) had diabetic retinopathy (DR). After 12 weeks of RASi treatment, significant decreases were observed within the UWF images in venous D Conclusion: RASi therapy might be associated with retinal peripheral venous alterations, providing clues to a vascular- and topography-specific therapeutic response and shedding light on a potential imaging biomarker for diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.